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Abstract: The purpose of this study was to determine the effect of the covalent 
incorporation of hyaluronic acid (HA) into conventional hydrogel and hydrogels containing 
silicone as models for contact lens materials on the uptake and release of the 
fluoroquinolone antibiotic ciprofloxacin and the anti-inflammatory steroid dexamethasone 
phosphate. A 3 mg/mL ciprofloxacin solution (0.3% w/v) and a 1 mg/mL dexamethasone 
phosphate solution (0.1%) was prepared in borate buffered saline. Three hydrogel material 
samples (pHEMA; pHEMA TRIS; DMAA TRIS) were prepared with and without the 
covalent incorporation of HA of molecular weight (MW) 35 or 132 kDa. Hydrogel discs 
were punched from a sheet of material with a uniform diameter of 5 mm. Uptake kinetics 
were evaluated at room temperature by soaking the discs for 24 h. Release kinetics were 
evaluated by placing the drug-loaded discs in saline at 34 °C in a shaking water bath.  
At various time points over 6–7 days, aliquots of the release medium were assayed for drug 
amounts. The majority of the materials tested released sufficient drug to be clinically 
relevant in an ophthalmic application, reaching desired concentrations for antibiotic or  
anti-inflammatory activity in solution. Overall, the silicone-based hydrogels (pHEMA 
TRIS and DMAA TRIS), released lower amounts of drug than the conventional pHEMA 
material (p < 0.001). Materials with HA MW132 released more ciprofloxacin compared to 
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materials with HA MW35 and lenses without HA (p < 0.02). Some HA-based materials 
were still releasing the drug after 6 days. 
Keywords: hyaluronic acid; silicone containing hydrogel; ciprofloxacin-HCl; dexamethasone 
phosphate; drug delivery 
 
1. Introduction 
Topical ophthalmic solutions, or eye drops, are used to deliver drugs to the anterior segment of the 
eye and account for approximately 90% of ophthalmic medications [1]. The use of eye drops as a drug 
delivery system to the eye has numerous advantages. Eye drops are simple and convenient for patient 
self-administration, and efficacious in treatment of medical conditions, since topical application 
delivers a high concentration of drug to the target site. However, a major disadvantage is low drug 
bioavailability. An instilled dose is in contact with the ocular surface for approximately 2 minutes, and 
only about 5% is absorbed into the eye [2], with most of it being lost to nasolacrimal drainage, spillage 
onto the cheek and conjunctival absorption. Blinking spreads the drop over the ocular surface and the 
conjunctiva becomes a major route of non-corneal absorption due to its larger surface area, 
vascularization and permeability compared to the cornea. Systemic absorption of the drug occurs 
through the conjunctiva and nasal mucosa in the nasolacrimal duct and may cause unwanted, adverse 
systemic effects. Rapid clearance from the ocular surface also means the drug has very little time to 
penetrate the cornea. The most effective corneal barrier is the epithelium, which is relatively 
impermeable due to the presence of tight junctions in the superficial layers, allowing only select small 
molecules to pass through, while largely excluding larger macromolecules. Since drug bioavailability 
and corneal penetration is low, topical ophthalmic solutions are formulated at higher concentrations 
and instilled multiple times a day in order to deliver an effective dose and equally importantly, prevent 
sub optimal dosing. Eye drops thus provide pulse delivery, with an initial transient overdose followed 
by a short period at therapeutic dose and then a prolonged period of sub-therapeutic dosing, 
necessitating the need for frequent instillation [3]. Patient compliance then becomes problematic, as 
the complexity of the dosing schedule increases. In addition, as the concentration of drugs increase, 
discomfort and irritation experienced by the patient also increases, further decreasing compliance [4]. 
The efficacy of the treatment regimen is further limited by problems with appropriate 
administration [5], and typically the same drop volume is not administered every time such that the 
drug is delivered at a variable rate.  
A potential, more efficient alternative to eye drops is a controlled release drug delivery system such 
as a drug-delivering soft contact lens or punctal plug. Soft contact lenses were first evaluated as a 
vehicle for ophthalmic drug delivery by Sedlacek in 1965 [6]. The objective was to provide slow, 
sustained drug release to the ocular surface, thus increasing bioavailability and penetration of the drug 
through the cornea. Intraocular absorption of a drug has been found to increase ten times when a  
drug-soaked contact lens was worn compared to instillation of eye drops [7], and this effect of 
improved bioavailability and ocular penetration has also been found with aminoglycosides and 
fluoroquinolone antibiotics [8]. Other studies comparing drug delivery with a soft contact lens to 
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subconjunctival injection found that higher drug penetration was achieved with soft contact lenses and 
was greater with higher water content lenses [9]. Drug loading into a hydrogel soft contact lens has 
been typically achieved by soaking the lens in drug solution or applying drops while the lens is being 
worn [10]. Either method improves drug retention on the ocular surface and corneal penetration, while 
simultaneously minimizing systemic absorption, although release kinetics typically mimic uptake 
kinetics. In these cases, the lenses act like drug reservoirs, because their highly porous structure and 
high water content enable diffusion of drugs into and out of the lens [11]. Limited mixing and 
exchange of the tear film underneath soft contact lenses also helps retain drug on the ocular surface 
longer than eye drops [12]. Improved corneal penetration suggests that lower concentration drug 
solutions could be used to attain therapeutic effects [9], which would also decrease the likelihood of an 
ocular adverse reaction. In addition, controlled delivery systems such as drug containing contact lenses 
have the potential to improve patient compliance because the treatment regimen would be simplified [13] 
and patients would have clear, comfortable vision since they can wear their refractive correction while 
being treated [10]. However, using commercial materials without any kind of modification has led to 
an inability to sustain drug release for more than a day and with a release profile that is characterized 
by a significant initial burst, followed by subtherapeutic dosing [3], suggesting that modification of the 
lens materials is necessary in order to achieved sustained, controlled drug release.  
Hyaluronic acid (HA), discovered by Meyer and Palmer in 1934 [14], is a high molecular weight, 
non-sulfated [15–17] glycosaminoglycan that occurs naturally throughout the body. It is mainly found 
in synovial fluid, vitreous, the umbilical cord, and loose connective tissues, such as the dermis.  
HA consists of unbranched, linear chains composed of repeating units of glucoronic acid and  
N-acetylglucosamine. These molecules aggregate to form a mesh-like sheet, which in larger numbers 
form molecular networks. HA is highly attractive to water, having 10–15 hydrogen bond accepting 
atoms per disaccharide unit [18], and swells to a much larger volume than that of its unhydrated 
state [19]. In solution, HA has an expanded random coil configuration and the chains are 
entangled [20]. The molecular weight of HA depends on its source and affects its physicochemical 
properties and physiological role [14]. HA networks regulate water movement, and transport and 
exclusion of molecules through its mesh-like structure [21]. HA plays an important structural role in 
connective tissues and acts as a lubricant and shock absorber in joints to protect against mechanical 
damage [20]. HA also has roles in cellular activities during embryonic development and 
morphogenesis, cell adhesion, inflammation, and tissue regeneration and repair [18].  
HA is a biocompatible, non-immunogenic, and biodegradable biomaterial. The medical applications 
of HA were pioneered by Balazs, who was the first to create non-inflammatory preparations of HA on 
a commercial scale to replace vitreous and aqueous humor in ocular surgery [22]. These preparations 
were also found to protect the corneal endothelium from damage during surgery. Commercial 
preparations containing HA have also been used as a viscosupplement in treating osteoarthritis, in 
surgery to prevent post-operative adhesions, and studied in wound healing, tissue engineering, and 
drug delivery [14]. HA solutions were found to have positive effects in ocular drug delivery studies. 
Studies from the late 1980s showed that adding HA to pilocarpine solutions improved bioavailability 
by increasing drug solution viscosity, so that ocular contact time was prolonged [23–26] and similar 
results were found for many other drugs [18]. It is also thought that mucoadhesion might play a role in 
the ability of HA to increase precorneal residence of a drug, because HA binds to the mucin layer on 
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the corneal epithelium [18,20]. We have previously developed a series of conventional and silicone 
hydrogel like materials containing HA [27,28]. When covalently attached to the polymer matrix, the 
presence of HA was found to change properties such as water uptake and protein interactions. Others 
have shown the presence of poly(ethylene glycol) in silicone materials can alter release kinetics and 
protect protein activity [29]. Therefore the presence of HA in these materials may facilitate drug 
release from silicone and silicone hydrogel like materials. While there have been numerous studies 
using HA as a release matrix, to-date there have been no studies using HA as an excipient to help 
facilitate release. We hypothesize based on the previous results with PEG that the presence of HA 
covalently incorporated into the hydrogel matrix can be used to control drug release. 
Ciprofloxacin (CF) is a broad-spectrum fluoroquinolone antibiotic available as a topical ophthalmic 
solution or ointment to treat bacterial conjunctivitis and bacterial corneal ulcers [30]. It is bactericidal 
to gram-negative and gram-positive bacteria by inhibiting the enzymes DNA gyrase (topoisomerase II) 
and topoisomerase IV that maintains the superhelical DNA structure during DNA synthesis. The 
treatment regimens for these infections are quite frequent due to inherent inefficiency of eye drops and 
the short CF residence time [31]. Treatment of even relatively mild bacterial conjunctivitis, for 
example, requires one to two drops four times a day, while treatment of sight threatening bacterial 
ulcers may have the drop instilled every fifteen minutes until further notice [30]. While adverse reactions 
are rare, the most frequently reported ones are localized burning, itching, foreign body sensation, 
formation of white precipitates associated with long-term use, redness, swelling, and photophobia.  
Dexamethasone phosphate (DXP) is a synthetic glucocorticoid, designed to enhance the  
anti-inflammatory properties of natural steroids produced by the adrenal glands. It is used 
ophthalmically to treat signs and symptoms of inflammation within the eye, including but not limited 
to redness, edema, heat and pain [32]. Prolonged treatment of the eye with dexamethasone has been 
linked to an increase in cataract formation, as well as an increase in intraocular pressure, potentially 
leading to glaucoma [33]. Regular monitoring of the intraocular pressure of patients being treated with 
dexamethasone is warranted. Use of dexamethasone or any steroid on the eye has the potential to 
exacerbate infection, and prolong wound healing times, thus it is used with caution [34].  
The purpose of this study was to measure uptake and release of ciprofloxacin and dexamethasone 
phosphate from HA-based conventional and silicone hydrogel (SH) model soft lens materials to 
evaluate the potential of these materials as drug delivery devices. 
2. Results and Discussion  
2.1. Ciprofloxacin-HCl Release from HA Materials 
Release curves over a 6-day period for ciprofloxacin loaded materials are presented in Figure 1(a–c). 
The discs are divided into three groups based on hydrogel material, either poly(2-hydroxyethyl 
methacrylate) (pHEMA), poly(2-hydroxyethylmethacrylate) tris(trimethylsiloxy)silylpropyl methacrylate 
(pHEMA TRIS) or N,N-dimethylacrylamide tris(trimethylsiloxy)silylpropyl methacrylate (DMAA 
TRIS). The release profiles from all three model materials showed similar patterns, with rapid initial 
release that slowed towards, but did not reach, a plateau. Ciprofloxacin release could be sustained for 
up to 6 days depending on the hydrogel type. pHEMA control discs and pHEMA + HA 132 kDa discs 
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released roughly similar amounts of ciprofloxacin, while pHEMA + HA 35 kDa discs showed slower 
release kinetics, with less drug being released in the first 12 h (Figure 1a). After 12 h, the highest 
ciprofloxacin release was seen from pHEMA controls discs, followed by pHEMA + HA 132kDa discs, 
then pHEMA + HA 35 kDa discs. At the end of 6 days, however, pHEMA + HA 132kDa discs 
released the highest total amount of ciprofloxacin (361 ± 5 µg), and pHEMA discs released the least 
(328 ± 13 µg).  
For the first 6 h, pHEMA TRIS and pHEMA TRIS + HA 132 kDa discs released roughly the same 
amount of ciprofloxacin, and pHEMA TRIS + HA 35 kDa discs released the least (Figure 1b). This 
seems to suggest that in these materials, higher molecular weight of HA interacts with the hydrophilic 
drug which led to a slower release, at least initially. After 6 h, pHEMA TRIS control discs showed 
slightly more ciprofloxacin release than pHEMA TRIS + HA 132 kDa discs, but at the end of 6 days, 
pHEMA TRIS + HA 132 kDa discs released the highest amount of ciprofloxacin (133 ± 22 µg), which 
was almost double what pHEMA TRIS + HA 35 kDa discs released (85 ± 0.4 µg) despite that fact that 
our previous studies have shown that the materials showed similar levels of water uptake. Therefore, 
the higher amounts of drug present in the materials containing 132 kDa HA are presumably due to 
interactions between the incorporated HA and the drug.  
Figure 1. Ciprofloxacin Release curves from (a) pHEMA, (b) pHEMA TRIS and (c) DMAA 
TRIS materials. Values plotted are means ± SD. HA 35 kDa = 35 kDa Hyaluronic Acid. 
HA 132 kDa = Hyaluronic Acid 132 kDa. 
 
(a) 
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Figure 1. Cont. 
 
(b) 
 
(c) 
Similar to the results with pHEMA TRIS, in the first hour, DMAA TRIS control discs and DMAA 
TRIS + HA 35 kDa discs released roughly similar amounts of ciprofloxacin, while pHEMA + HA  
132 kDa discs released more (Figure 1c). After one hour, pHEMA + HA 132 kDa discs continued to 
show the highest release, (86 ± 22 µg), and DMAA TRIS + HA 35 kDa discs began to show higher 
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ciprofloxacin release than DMAA TRIS control discs, the difference increasing as time went on. These 
results clearly suggest that the presence of HA in the materials in general leads to increased uptake of 
the ciprofloxacin and hence, greater release. The lowest ciprofloxacin release was from DMAA TRIS 
control discs, at 49 ± 3 µg.  
However, in all cases, the kinetics of release was similar. All discs showed a similar and expected 
pattern of drug release, with initially rapid kinetics followed by decreasing release over time, which 
suggests that there were no interactions between the HA and the drug. This type of square root time 
release profile has been observed in several other studies that looked at ciprofloxacin release from soft 
contact lenses over a period of 24 h or less [8,23,35–37]. Unlike the commercially available contact 
lenses in those studies, most of these HA-based model lens materials showed measurable ciprofloxacin 
release for up to six days. Some authors [38] also found that adding HA to their hydrogel resulted in 
sustained ciprofloxacin release, which increased as the content of HA was increased. However, in 
these materials, the HA formed the gel. In these materials, a low degree of methacrylation of the HA 
ensured that the HA was incorporated along the polymer backbone. The thickness of these materials 
may have played a role in the extended release profiles observed compared with the swollen contact 
lenses previously examined, although more than 7 fold increase in the release time would not be 
expected based on the increased thickness of the materials. As well, there is some linearity in the first 
12 h of ciprofloxacin release that is an improvement over the release profiles of commercial contact 
lenses that release most of their drug within 24 h.  
The average total mass of ciprofloxacin released over the 6 day period from each of the samples is 
presented in Table 1. Ciprofloxacin release was higher for materials with added 132 kDa HA than  
35 kDa HA, but this difference was also not found to be statistically significant (p > 0.05). Studies by 
other authors did find that different molecular weights of HA affected drug delivery [26]. They 
compared high- and low-molecular-weight fractions of HA in pilocarpine solutions and found that 
adding higher MW HA produced better ocular retention times. In a volume of 2 mL, all discs released 
enough ciprofloxacin to meet the minimum inhibitory concentration (MIC90) previously demonstrated 
for many common ocular pathogens [35].  
Table 1. Total mass (µg) of ciprofloxacin released from all model lens materials. 
Modification None (control) HA 35 HA 132 
Material mean SD mean SD mean SD 
pHEMA 328 13 337 33 361 5 
pHEMA TRIS 99 12 85 0.4 133 22 
DMAA TRIS 48 3 68 5 86 22 
The rate of drug release is important because in an ophthalmic application, the tear film is drained 
and replenished at a regular rate. While these materials are thicker than a typical contact lens and 
therefore cannot be taken as representative of lens materials, for use in front of the eye application, the 
delivery system must be able to maintain effective concentrations of drug throughout the prescribed 
wearing period, as unabsorbed drug is eliminated from the ocular surface. Slower release rates enable 
more drug to be absorbed into the eye rather than into the systemic system [10]. All discs released the 
highest concentration of ciprofloxacin during the first hour. In the second hour, the concentration of 
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drug released decreased to at least half the rate and continued to decrease for the remainder of the 
testing period. Only pHEMA TRIS + 132 kDa HA discs released concentrations of ciprofloxacin per 
hour that met the MIC90 for up to 6 days. However, the systems were swollen in a relatively low 
concentration solution of the ciprofloxacin; swelling in higher concentrations of the drug could be used 
to increase drug release.  
Ciprofloxacin is not very soluble at physiological pH [35] so the discs were visually inspected for 
white precipitates. During the release phase, white precipitate films were seen on the surfaces on 
pHEMA TRIS + HA 132 kDa discs (Figure 2) and loose, white precipitate clumps were loosely 
attached to the surfaces of DMAA TRIS + HA 35 kDa discs (Figure 3). All other discs were clear of 
white precipitates. Ciprofloxacin precipitation does not require cessation of treatment [30], but it may 
interfere with the optical performance. Therefore, careful consideration of the material drug interaction 
is critical in the eventual usefulness of these types of devices and may warrant further investigation. 
Figure 2. Ciprofloxacin precipitate film on the surfaces of pHEMA TRIS + HA 132 kDa disc. 
 
Figure 3. Ciprofloxacin precipitate on the surfaces of DMAA TRIS + HA 35 kDa disc. 
 
2.2. Dexamethasone Release from HA Materials 
Release results for the dexamethasone phosphate loaded materials are presented in Figure 4(a–c). 
Again, the release curves are organized based on hydrogel material. Similar types of release patterns 
were seen, with the rate of drug release slowing over time, and moving toward a plateau. Sustained 
release of dexamethasone was seen with some materials for the 7 day monitoring period. pHEMA 
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control materials released the largest amount of dexamethasone over the 7 day period (Figure 4a). 
While the pHEMA + HA 35 kDa and pHEMA + HA 132 kDa released less than the pHEMA control, 
the amount released was greater than from any other material, with no statistically significant 
difference between the two molecular weights of HA using pHEMA based discs (p > 0.05). 
Figure 4. Dexamethasone phosphate release curves from (a) pHEMA, (b) pHEMA TRIS 
and (c) DMAA TRIS materials. Values plotted are means ± SD. HA 35 kDa = 35 kDa 
Hyaluronic Acid. HA 132 kDa = Hyaluronic Acid 132 kDa. 
 
(a) 
 
(b) 
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Figure 4. Cont. 
 
(c) 
Similar results were seen between the two materials modified with the TRIS silicone component. 
For the first 6 h, the pHEMA TRIS + HA 35 kDa and pHEMA TRIS + HA 132 kDa model lenses 
released more dexamethasone and over a more prolonged period of time than the pHEMA TRIS 
control (Figure 4b), as did the DMAA TRIS + HA 35 kDA and DMAA TRIS + HA 132 kDa 
compared to the DMAA TRIS control. For pHEMA TRIS model lenses, all model lenses eventually 
released similar amounts of dexamethasone phosphate after 7 days (p > 0.05). For DMAA TRIS model 
lenses on the other hand, there was a statistically significant greater amount of drug released after  
7 days for the HA modified materials versus the control. 
All of the dexamethasone loaded materials released significant amounts of dexamethasone.  
All pHEMA materials released a significant amount of dexamethasone within 45 minutes. The 
incorporation of a more hydrophobic TRIS component led to slower release rates and generally lower 
amounts of released drug, although the latter is presumably due to lower loading with the lower 
swelling of the TRIS containing materials. The total amount of dexamethasone released from each 
model material is summarized in Table 2. The pHEMA based materials released statistically 
significantly more dexamethasone than the TRIS incorporated materials, although surprisingly release 
amounts from the pHEMA materials were not increased by the increased swelling that we have 
previously demonstrated accompanies the incorporation of HA. In DMAA TRIS, incorporation of HA 
led to a statistically greater amount of HA to be released (p < 0.002). The effect of HA was not 
significant for pHEMA TRIS based materials (p > 0.05). 
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Table 2. Total mass (µg) of dexamethasone phosphate released from all model lens materials.  
Modification None (control) HA 35 HA 132 
Material mean SD Mean SD mean SD 
pHEMA 109 15 53 5 57 6 
pHEMA TRIS 12 1 13 0.7 13 0.9 
DMAA TRIS 13 0.6 23 2 21 1 
Previous work with contact lenses has shown that drug penetration and subsequent release depends 
on material properties as well as the properties of the drug and drug-loading solution [9,10]. For a 
given lens material, different drugs have different diffusion coefficients and different solubilities [10]. 
Drug uptake and release are affected by such lens properties as lens polymer, water content,  
three-dimensional structure and lens thickness. There is evidence that higher water content lenses show 
greater drug uptake in general [10,39], while some evidence suggests that lower water content lenses 
show longer release times [10]. Conventional hydrogels are generally considered more porous than SH 
hydrogels [40] so it is likely that the higher amounts of drug released from the pHEMA materials was 
the result of increased loading of the drug in these materials, presumably due to their higher water 
content. SH materials have a relatively low water content compared to conventional hydrogels and 
those containing TRIS take up less water [41], which might have resulted in lower drug uptake, and 
consequently, lower release than the conventional hydrogel. HA increases water uptake into the lens 
when incorporated into the hydrogel matrix [41,42], which might also have contributed to higher 
absorption by lens materials with HA.  
It is important to consider the characteristics of soft lenses themselves when selecting a material to 
manufacture therapeutic lenses. They should still be able to provide clear, comfortable vision, but also 
be safe to wear for the prescribed period of time. Hydroxyethylmethacrylate (HEMA) is a commonly 
used conventional lens material but lenses made from this material are limited in their ability to 
transmit oxygen by their low water content and lens thickness [40]. Silicone hydrogel (SH) soft lens 
materials were developed relatively recently, in which siloxane moieties were added to the polymer for 
improved oxygen permeability. SH lenses have the wettability and comfort of conventional hydrogel 
lenses, but are far better able to meet the oxygen demands of the cornea so that they are safer for 
extended wear in which the lenses are worn overnight, following eye closure, and may be useful for 
extended drug release. In addition to altering the release kinetics shown in this work, recent studies 
have shown that there is reduced protein adsorption on HA-based lenses, which increases wettability 
and comfort [41,42].  
3. Experimental Section 
3.1. Solution Preparation 
A 3 mg/mL (0.3%) ciprofloxacin solution (Sigma, Oakville, ON, USA) was prepared in Unisol®4 
(Alcon®, Fort-Worth, TX, USA), an unpreserved ophthalmic borate buffer solution. A 0.3% 
ciprofloxacin solution was used in this study to match commercially available topical ophthalmic 
ciprofloxacin solutions. The pH was adjusted to approximately pH 4.0 with hydrochloric acid to ensure 
complete solubility of ciprofloxacin [35]. A 1 mg/mL (0.1%) dexamethasone phosphate solution was 
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also prepared in Unisol®4. Linear standard curves were created from the stock drug solution to convert 
fluorescence readings into concentrations. Amber vials were used throughout the experiment to 
minimize light exposure to the drugs, which are light sensitive. 
3.2. Model Materials 
2-Hydroxyethyl methacrylate (HEMA), ethylene glycol dimethacrylate (EGDMA) and  
N,N-dimethylacrylamide (DMAA) were purchased from Sigma-Aldrich (Oakville, ON, Canada). 
tris(trimethylsiloxy) silylpropylmethacrylate was purchased from Gelest (Morrisville, PA, USA) and 
IRGACURE was purchased from CIBA (Mississauga, ON, Canada). The HEMA and TRIS was passed 
through Aldrich inhibitor removers to remove the polymerizer inhibitor 4-methoxyphenol (MEHQ). All 
other reagents were used as received. Three soft hydrogel materials, poly-HEMA (pHEMA), pHEMA 
TRIS and DMAA TRIS were prepared with and without covalent incorporation of HA of molecular 
weight (MW) 35 or 132 kDa as previously described. Briefly, after passing through the inhibitor 
removers, 3.6 g of HEMA was mixed with 0.4 g TRIS (90:10 HEMA:TRIS ratio) and 0.2 g of 
EGDMA. 0.02 g of IRGACURE was added, and the solution was mixed before being cured for  
20 minutes in a UV Chamber (CureZone 2 Cont-Trol-Cure) in aluminum molds. DMAA TRIS 
materials were made in a similar fashion, but with 2.0 g of DMAA added to 2.0 g of TRIS (50:50 
DMAA:TRIS ratio), with the weight of the other reagents and the curing process the same. HA was 
methacrylated and incorporated into the hydrogel materials during UV polymerization. Hydrogel discs 
were punched out from a sheet of material. The discs had a uniform diameter of 5 mm and a dry 
weight of 0.034 g +/− 0.006 g, and varied in thickness from 0.93 mm to 1.84 mm.  
3.3. Drug Loading 
At room temperature, three discs of a given model hydrogel type were rehydrated in Unisol®4  
for 24 h and then placed in a solution of 3 mg/mL ciprofloxacin or 1 mg/mL dexamethasone phosphate 
for 24 h. 
3.4. Release Kinetics 
The lens discs from the uptake phase were transferred into Unisol®4 after surface residual drug 
solution was removed with a brief rinse in Unisol®4. To approximate in-eye conditions, the lens discs 
were incubated at 34 °C in a shaking water bath rotating at 100 RPM and released into phosphate 
buffered saline (pH 7.4). Aliquots of the ciprofloxacin solution were removed at specified time points 
and measured on a Hitachi F-4500 Fluorescence Spectrophotometer (Hitachi Ltd., Tokyo, Japan) at  
274 nm excitation and 419 nm emission wavelengths. Aliquots of the dexamethasone solution were 
removed at specified time points and measured on a Hitachi UV-2010 spectrophotometer (Hitachi Ltd., 
Tokyo, Japan) at an absorbance of 241 nm. 
3.5. Analysis 
Data analysis was conducted using a repeat measures ANOVA with time as a within-subject effect 
and lens material as a between subject factor, and posthoc analysis was done using Tukey HSD 
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(Statistica Ver8, Statsoft Inc., Tulsa, OK, USA). A significance level of p < 0.05 was considered 
significantly different.  
3.6. Photographs 
Photographs of the lens discs were taken using a Canon PowerShot A640 digital camera under 
natural lighting to show the presence of white precipitates on their surfaces. 
4. Conclusions 
Hyaluronic-acid containing materials may be an advantageous vehicle in drug delivery, particularly 
for more hydrophobic drugs. Simply swelling the HA modified lens materials in pharmacologically 
relevant solutions of the drug increased the amount of drug released and resulted in extended release 
that continued for up to 6 days. Although the silicone hydrogel materials released less ciprofloxacin 
and dexamethasone phosphate than the conventional hydrogel materials, release amounts were sufficient 
to be effective against common susceptible and resistant ocular pathogens or to suppress inflammation 
and the amount released could likely be tailored by changing uptake kinetics or solution concentrations. 
Ciprofloxacin precipitation on the silicone containing materials suggests that the hydrophobic 
character of these materials however may limit their potential use in ophthalmic applications.  
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